...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine (published erratum appears in J Cancer Res Clin Oncol 1998;124(11):641)
【24h】

Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine (published erratum appears in J Cancer Res Clin Oncol 1998;124(11):641)

机译:导致白血病细胞系亚系对抗肿瘤药物9-β-D-阿拉伯呋喃糖基-2-氟腺嘌呤产生抗性的机制(发表的勘误表见J Cancer Res Clin Oncol 1998; 124(11):641)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

An agent 9-beta-D-arabinofuranosyl-2-fluoroadenine (2-F-Ara-A) is a main metabolite of fludarabine, a fluorinated purine analogue with antitumor activity in lymphoproliferative malignancies. In this study, the mechanism responsible for the resistance of cancer cells to fludarabine was examined using the 2-F-Ara-A-resistant sublines JOK-1/F-Ara-A and L1210/F-Ara-A from a human hairy leukemic cell line (JOK-1) and a mouse leukemic cell line (L1210) respectively, which were established by continuous treatment of the parental cell lines with 2-F-AraA. JOK-1/F-Ara-A and L1210/F-Ara-A cells were more than 55 and 29 times more resistant to 2-F-Ara-A than were their parent cell lines, and showed a high cross-resistance to 1-beta-D-arabinofuranosylcytosine but not to doxorubicin or vincristine. These resistant sublines intracellularly accumulated almost the same amount of 2-F-Ara-A as did their parent cell lines. However, the amount of 2-F-Ara-ATP, a cytotoxic metabolite of 2-F-Ara-A, decreased by 2.6% (JOK-1/F-Ara-A C3), 6% (L1210/F-Ara-A C1) and 3.7% (L1210/F-Ara-A C7) relative to the levels in the parent cell lines. Enzymatically, these resistant cells hardly activated deoxycytidine (dCyd) and 2-F-Ara-A. In addition, the abilities to phosphorylate deoxyadenosine and deoxyguanosine were also decreased in the resistant cells in comparison with the parent cells. These findings suggest that the deficiency in activity of dCyd kinase may contribute to the resistance of 2-F-Ara-A.
机译:药物9-β-D-阿拉伯呋喃糖基-2-氟腺嘌呤(2-F-Ara-A)是氟达拉滨的主要代谢物,氟达拉滨是一种氟嘌呤类似物,在淋巴增生性恶性肿瘤中具有抗肿瘤活性。在这项研究中,使用人毛发的2-F-Ara-A耐药亚系JOK-1 / F-Ara-A和L1210 / F-Ara-A检查了导致癌细胞对氟达拉滨耐药的机制。白血病细胞系(JOK-1)和小鼠白血病细胞系(L1210),分别通过用2-F-AraA连续处理亲本细胞系而建立。 JOK-1 / F-Ara-A和L1210 / F-Ara-A细胞对2-F-Ara-A的抵抗力是其亲本细胞系的55倍和29倍以上,并且对1-β-D-阿拉伯呋喃糖基胞嘧啶,但对阿霉素或长春新碱不敏感。这些抗性亚系在细胞内积累的2-F-Ara-A量与其亲本细胞系几乎相同。但是,2-F-Ara-A的细胞毒性代谢产物2-F-Ara-ATP的量分别降低了2.6%(JOK-1 / F-Ara-A C3),6%(L1210 / F-Ara -A C1)和3.7%(L1210 / F-Ara-A C7)相对于亲本细胞系的水平。在酶学上,这些抗性细胞几乎不活化脱氧胞苷(dCyd)和2-F-Ara-A。另外,与亲代细胞相比,抗性细胞中磷酸化脱氧腺苷和脱氧鸟苷的能力也降低了。这些发现表明,dCyd激酶活性的不足可能导致2-F-Ara-A的抗性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号